A Clinical Study to Evaluate the Safety and Efficacy of Platelet Rich Plasma Injection for Atrophic Rhinitis

NCT ID: NCT03112330

Last Updated: 2019-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-08

Study Completion Date

2019-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the suggested research is to develop a treatment option using platelet rich plasma injection for regeneration of atropic nasal mucosa.

Specific aims of the suggested research is to (1) access the effect of platelet rich plasma in the patients with atropic rhinitis . Moreover, we will (2) compare the conservative treatments including saline nasal irrigation or saline nasal spray.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clinical trials of platelet rich plasma injection for regeneration of atropic nasal mucosa.

* Injection interval and follow-up duration

* Injection interval 2 weeks (upto total 3 consecutive injection)
* Follow-up duration: 6 months
* Observation items, clinical assessment items and evaluation method

* Access the nasal mucosal status using nasal speculum.
* Access the nasal mucociliary function using saccharin test (primary outcome; once per month).
* Fill in the nasal symptom scores using Nasal Obstruction Symptom Evaluation(NOSE) Instrument, Sino-Nasal outcome Test 20, and Visual analog scale (secondary outcome; once per month)
* The other atrophic rhinitis patients who did not want to perform platelet rich plasma injection

* Random allocation to saline nasal irrigation or saline nasal spray group
* Perform same observation items, clinical assessment items and evaluation method as well as platelet rich plasma injection group

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrophic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Platelet Rich Plasma Injection group : 12 patients anticipated Saline spray group : 12 patients anticipated
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

platelet rich plasma injection group

To evaluate the safety and efficacy of plasma rich platelet injection on inferior turbinate mucosa in patients with atrophic rhinitis

Group Type EXPERIMENTAL

Plasma rich platelet injection

Intervention Type DEVICE

Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa

Saline nasal spray

Intervention Type DEVICE

two puffs of isotonic saline nasal spray twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plasma rich platelet injection

Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa

Intervention Type DEVICE

Saline nasal spray

two puffs of isotonic saline nasal spray twice daily

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (\>18 years)
* Complaint of atrophic rhinitis symptoms including nasal crusting, nasal burning sensation, and postnasal drip
* Atrophic rhinitis view on nasal endoscopic finding
* Patients who informed sufficient about other atrophic rhinitis treatment options including Young's operation, lubricants, or saline irrigation, but, want more other active treatment option.

Exclusion Criteria

* Platelet related disorders
* Low serum platelet (\<100,000/㎕)
* Other hematologic disorders
* Septicemia
* Take anticoagulant drugs
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul St. Mary's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sung Won Kim

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sung Won Kim, MD, PhD

Role: STUDY_CHAIR

Seoul St. Mary's Hospital

Do Hyun Kim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Seoul St. Mary's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul St. Mary's Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Friji MT, Gopalakrishnan S, Verma SK, Parida PK, Mohapatra DP. New regenerative approach to atrophic rhinitis using autologous lipoaspirate transfer and platelet-rich plasma in five patients: Our Experience. Clin Otolaryngol. 2014 Oct;39(5):289-92. doi: 10.1111/coa.12269. No abstract available.

Reference Type BACKGROUND
PMID: 24938860 (View on PubMed)

Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004 Apr;62(4):489-96. doi: 10.1016/j.joms.2003.12.003. No abstract available.

Reference Type BACKGROUND
PMID: 15085519 (View on PubMed)

Hildenbrand T, Weber RK, Brehmer D. Rhinitis sicca, dry nose and atrophic rhinitis: a review of the literature. Eur Arch Otorhinolaryngol. 2011 Jan;268(1):17-26. doi: 10.1007/s00405-010-1391-z. Epub 2010 Sep 29.

Reference Type BACKGROUND
PMID: 20878413 (View on PubMed)

Mishra A, Kawatra R, Gola M. Interventions for atrophic rhinitis. Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD008280. doi: 10.1002/14651858.CD008280.pub2.

Reference Type BACKGROUND
PMID: 22336840 (View on PubMed)

Jaswal A, Jana AK, Sikder B, Nandi TK, Sadhukhan SK, Das A. Novel treatment of atrophic rhinitis: early results. Eur Arch Otorhinolaryngol. 2008 Oct;265(10):1211-7. doi: 10.1007/s00405-008-0629-5. Epub 2008 Mar 4.

Reference Type BACKGROUND
PMID: 18317788 (View on PubMed)

Modrzynski M. Hyaluronic acid gel in the treatment of empty nose syndrome. Am J Rhinol Allergy. 2011 Mar-Apr;25(2):103-6. doi: 10.2500/ajra.2011.25.3577.

Reference Type BACKGROUND
PMID: 21679513 (View on PubMed)

Canciani M, Barlocco EG, Mastella G, de Santi MM, Gardi C, Lungarella G. The saccharin method for testing mucociliary function in patients suspected of having primary ciliary dyskinesia. Pediatr Pulmonol. 1988;5(4):210-4. doi: 10.1002/ppul.1950050406.

Reference Type BACKGROUND
PMID: 3237448 (View on PubMed)

Stavrakas M, Karkos PD, Markou K, Grigoriadis N. Platelet-rich plasma in otolaryngology. J Laryngol Otol. 2016 Dec;130(12):1098-1102. doi: 10.1017/S0022215116009403.

Reference Type BACKGROUND
PMID: 27938467 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CMCENT-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.